Fred Furry, COO & CFO

December 4, 2012

Nasdaq: BIOL

PAGE

1

Exhibit 99.1

PAGE

2

Safe Harbor Statement

This presentation may contain forward-looking statements that are based on our current expectations, estimates and

projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,”

“expects,”

“intends,”

“plans,”

“believes,”

“seeks,”

“estimates,”

“may,”

“will,”

and variations of these words or similar

expressions are intended to identify forward-looking statements. These statements include projections about our future

earnings and margins and speak only as of the date hereof. Such statements are based upon the information available

to us now and are subject to change. We will not necessarily inform you of such changes. These statements are not

guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to

predict. Therefore our actual results could differ materially and adversely from those expressed in any forward-looking

statements as a result of various factors. The important factors

which

could

cause

actual

results

to

differ

materially

from those in the forward-looking statements include, among others, a downturn or leveling

off of demand for our

products due to the availability and pricing of competing products and technologies, adverse international market or

political conditions, a domestic economic recession, the volume and pricing of product sales, our ability to control costs,

intellectual property disputes, the effects of natural disasters

and other events beyond our control and other factors

including those detailed in BIOLASE’s filings with the Securities and Exchange Commission including its prior filings on

Form 10-K and 10-Q.

•

We are a biomedical company focused on developing, manufacturing, and

selling dental lasers using our revolutionary, proprietary WaterLase technology.

•

Also a marketer & distributor of:

–

dental imaging equipment,

–

intra-oral scanners, and

–

other products designed for dental & medical procedures.

•

Net revenue of $48.8M in 2011; up 87% over 2010.

•

Projecting gross revenue of $55M to $58M in 2012.

BIOLASE Company Overview

Step

Technology

BIOLASE Product Offering

Diagnose and establish

treatment protocol

3D cone beam imaging

•

NewTom

(QR/Cefla)

•

DaVinci Imaging

(Cefla)

Treatment: all tissue surgical

device

WaterLase

•

WaterLase iPlus

•

WaterLase MDX

•

WaterLase MD Turbo

Treatment: soft tissue

surgical device

Diode laser

•

EPIC 10

diode laser

•

iLase

portable, battery operated diode

laser

Impression taking for crowns

Digital

•

TRIOS

intra-oral scanner (3Shape)

PAGE 4

BIOLASE’s Total Technology Solution

•

WaterLase is a biological method to cut tissue.

•

Water molecules within tissue absorb the laser energy from

the WaterLase, expand, and vaporize, which causes a

biological ablation of the tissue.

–

There is very little trauma or bleeding,

–

No heat or vibration are generated, and

–

Causes little or no pain.

–

Significantly reduces cross contamination.

WaterLase All-Tissue Lasers

•

Extensive patent protection.

How It Works: WaterLase High Speed Cutting

PAGE 6

WaterLase Side by Side with Drill

PAGE

7

WaterLase Soft Tissue Lingual Frenectomy

PAGE

8

WaterLase Atraumatic Pediatric Tooth Extraction

The WaterLase

aiming beam 

does not cut the

tissue or generate

heat.  The tissue

is cut biologically,

with little or no

pain, when the

laser energizes

water at the

molecular level.

PAGE 9

2

•

176,000 dentists in US & Canada.

•

1.2M   dentists in 134 countries.

–

rapid growth in emerging economies

e.g. China, India & Indonesia.

•

Current market penetration .

–

approx. 5.0% of dental practices in US.

–

approx. 1.5% worldwide.

•

Each incremental 1% market penetration equals over $600M revenue.

•

Total market opportunity is in excess of $50B.

1 

BIOLASE’s Market Opportunity

Est. total global market

BIOLASE systems sold worldwide 1998-present

1

American Dental Association. 

2

World Federation of Dentistry. 

PAGE 10

1,200,000

20,000+

+

Dominant Market Position

Hard-tissue Dental Laser Market

Total Dental Laser Market

80%

45%

BIOLASE Market Share

•

EPIC 10 total diode solution

–

regulatory clearance late Q3 (EU) & early Q4 (US) 2012.

–

cleared for 3 unique uses:

Pain Therapy.

•

iLase

–

portable diode laser.

–

no foot pedal, power cord, or external controls.

Diode Soft-Tissue Dental Lasers

Soft Tissue Surgery,

Whitening,

•

TRIOS intra-oral

scanner and cart

–

digital impression

taking.

–

handheld scanner,

operator's control

cart, and software.

–

North American

distribution

agreement through           

Aug 2017.

In-Licensed Products

•

NewTom and Cefla

3D cone beam

imaging products

–

medical grade

imaging

technology.

–

less cost, less

radiation exposure.

–

U.S. & Canada

distribution

agreement through

Feb 2015.

PAGE 14

•

291 patents issued & pending

•

70% are related to WaterLase technology & medical lasers

Extensive Patent Portfolio

Issued &

Active

Pending

Total

133

158

291

52

77

129

81

81

162

U.S.

International

Total

•

Returned to direct sales model in N. America in August 2010

•

Currently consists of 47-person team:

–

37 direct outside sales

–

10 inside sales representatives and lead generators

–

Current:

Irvine,

CA

(USA),

Floss

(Germany),

Madrid

(Spain),Shanghai

(China),

and Mumbai (India)

–

Planned: Dubai (UAE) and Rio de Janero (Brazil)

Sales and Marketing

•

Targeted plans for 42-45 outside reps and 12-15 inside reps

•

Global sales offices

Gross Revenue and Influencers

Launched

Cefla’s NewTom

Cone Beam

Imaging products

Introduced iLase™

hand-held soft-

tissue diode laser

Introduced DaVinci

Imaging™

products

Launched

WaterLase

®

iPlus™

all-tissue laser

TRIOS™

intra-oral

scanner

CE Mark & FDA

clearance for EPIC 10

Ended exclusive

distribution

agreement w.

Schein

Introduced

WaterLase

®

MDX™

all-

tissue lasers

$20.0

$15.0

$10.0

$5.0

$0.0

Q1 '10

Q2 '10

Q3 '10

Q4 '10

Q1 '11

Q2 '11

Q3 '11

Q4 '11

Q1 '12

Q2 '12

Q3 '12

Q4 '12

$4.4

$5.9

$6.2

$9.7

$10.6

$12.1

$13.1

$13.2

$12.3

$13.3

$13.8

$16.5-17.5

Launched 3Shape’s

•

Continued adoption of core WaterLase products.

•

Drive sales of EPIC 10 diode soft-tissue laser.

•

Growth of Imaging Division (cone beam and cad-cam)

•

Additional new product introductions based on our core technologies.

–

Two

510(k) submissions currently under FDA review.

–

Three additional submissions planned to be filed in near term.

•

Expand into new markets beyond dentistry.

Growth Strategy

•

Ongoing growth in WaterLase sales.

•

Recent & planned new product introductions.

–

EPIC 10 & TRIOS introduced second half of 2012.

–

Additional product launches based on core technologies planned.

•

Strong IP protection with additional patents pending.

•

Addressing $50 dental laser market opportunity.

–

Significant opportunities in other medical markets.

•

Improved financial position.

Investment Considerations

BIOLASE Corporate Headquarters in Irvine, California       

PAGE 19

•

Over 180 employees worldwide

•

Sales offices in Floss (Germany), Madrid (Spain),

Shanghai (China), and Mumbai (India); expansion

planned in Dubai (UAE), and Rio de Janero (Brazil)

•

Floss also has service and manufacturing capabilities

BIOLASE Europe in Floss, Germany

•

Corporate HQ: Irvine, California

•

57,000 sq. ft. facility houses finance &

administrative, sales, marketing, customer care,

training, manufacturing, and R&D

•

Can accommodate growth to $250 million

BIOLASE Today

Fred Furry

COO & CFO, BIOLASE, Inc.

949.226.8124

ffurry@biolase.net

PAGE 20

Lisa Wilson

President, In-Site Communications, Inc.

212.759.3929

lwilson@insitecony.com